Tuesday, October 14 2025

Using IPO proceeds, Pakistan’s BF Biosciences launches Zeptide to expand diabetes portfolio
In a major boost to Pakistan’s pharmaceutical sector, BF Biosciences Limited has introduced Zeptide (Tirzepatide), an advanced dual-action therapy for Type 2 diabetes and obesity, developed and manufactured at its local facility. The pharma shared the development in its notice to the Pakistan Stock Exchange (PSX) on Tuesday. Tirzepatide, approved by the US Food and Drug Administration (FDA), is a synthetic polypeptide that acts as a dual agonist for GLP-1 and GIP receptors, offering a breakthrough approach in managing blood glucose levels and promoting weight reduction, according to a statement.
Related news categories: business economic-indicators pharma psx stock-exchanges
Related symbols: bfbio (news stock)